Within recent years needle biopsy of the liver has become an excellent research as well as diagnostic tool, and the observations made available by this technique have both theoretical and practical significance. With its aid, base-line observations of liver morphology may be made and periodic sampling thereafter may reflect the changes occurring in this organ as a result of drug therapy.
Case $2. S. R., a 52-year-old white male, was admitted to the hospital on February 1, 1950 with a febrile illness associated with a 25-pound weight loss and epithelioid granulomata of the lymph nodes and bone marrow. Liver biopsy done on 2/18/50, following a maximum weight loss, showed large granulomata present mid-zonally and sharply circumscribed by envelopes of fibrous tissue. There was no fat in the parenchymal cells (Fig. 4) . The differential diagnosis included sarcoidosis and brucellosis. Because of the latter, although no positive cultures were obtained, aureomycin, 4.0 grams daily, was administered from March 8 through March 28, the patient receiving a total of 84 grams. A repeat liver biopsy on April 2 revealed a moderate degree of small cell vacuolization of the parenchymal cells, particularly in the central areas of the lobules. The vacuoles tended to be about the size of parenchymal cell nuclei or smaller (Fig. 5) . No b. In one of the three cases (Case #1) with fatty metamorphosis of the liver, a 44-day post-treatment liver biopsy revealed an occasional large fatty vacuole, which was also present in the pretreatment biopsy.
c. These findings suggest that aureomycin was responsible for fatty change in the liver. It is unlikely that the disease per se produced the fatty change observed in Case #1, a chronic relapsing disease, or in Case #2, a chronic disease, or in Case #3, an acute disease. Pretreatment biopsies in each case showed absence of fatty change. Furthermore, the biopsy in Case #2 was done at a time when weight loss was at a peak. The fatty change in Cases #2 and #3 occurred only after aureomycin therapy, at a time when the patients were improving clinically and were afebrile. Furthermore, it is unlikely that a sampling error occurred in these adequate biopsies, because it is our experience that when fatty change occurs in the liver it is of remarkably uniform lobular distribution. Waldstein and Szanto8 have also recently demonstrated that with respect to fatty metamorphosis and injury of the epithelial liver cells, multiple needle biopsy specimens are almost always uniform throughout the liver.
d. In Case #2 the patient developed a mild transient cheilosis at the angles of the mouth for one week immediately following the cessation of aureomycin therapy. This is similar to the riboflavin deficiency described by Harris.' The mechanism involved is either an interference with the absorption or utilization of riboflavin because of the induced change in the intestinal flora, or a defect in utilization caused by aureomycin's interfering with the enzyme systems. It is possible that similar mechanisms may cause a deficiency of lipotropes in association with aureomycin therapy, resulting in fatty metamorphosis of the liver. There was no clinical evidence of vitamin deficiency in Cases #1 and #3.
Terramycin. In the following case, the effects of terramycin therapy were noted.
Case $5. T. M. W., a 32-year-old white male with typhoid fever was given 28.5 grams of terramycin from August 26 to September 4, 1950. Liver biopsy on the sixth day of terramycin therapy, after 17 grams, revealed absence of fatty metamorphosis.
Klatskin' has found fatty metamorphosis, similar to that seen following aureo,mycin therapy, in one case two days after cessation of terramycin therapy, in which 72 grams were given over a 16-day period. Control liver biopsy four days prior to terramycin therapy revealed no fat. In a second case, marked fatty metamorphosis of the liver was seen following the administration of 31 grams of terramycin over a 9-day period. The control liver biopsy one day prior to the institution of therapy was normal. This is in contrast to Case #5, in which no fatty metamorphosis was found in the liver at a time when only 17 grams of terramycin over a period of six days had been administered. Comment. One case treated with combined tibione and streptomycin (Case #10) developed hepatitis, which was probably homologous serum jaundice since it subsided during continued treatment. In the two other cases treated with combined tibione and streptomycin, no evidence of morphologic change was seen in the liver parenchyma. In the one case treated with tibione, streptomycin, and para-amino-salicylic acid, there was similarly no morphologic change in the liver.
Chloromycetin. The following case was treated with Chloromycetin.
Case X13. A. S., a 28-year-old white male, was admitted to the hospital on July 11, 1950 because of an acute osteomyelitis of the right tibia. Incision and drainage of the osteomyelitic abscess were carried out on 7/12/50 and culture of the pus obtained revealed a pure growth of Aerobacter aerogenes. Chloromycetin (chloramphenicol), 2.0 grams daily, was started on 7/14/50. After the patient had received a total of 19.5 grams of Chloromycetin, a liver biopsy was performed on 7/24/50 and revealed normal hepatic tissue. No fatty metamorphosis was present. Summary 1. Three of four cases treated with aureomycin showed fine fatty metamorphosis of the liver at the end of thirteen to twenty days of treatment. Forty-four-day post-therapy biopsy in one of these revealed loss of fat.
2. One case treated with terramycin showed no fatty metamorphosis of the liver at the end of six days of therapy. Klatskin' has observed fatty metamorphosis in two patients following a larger quantity administered over a longer period.
3. Seven cases treated with tibione and various combinations of tibione, streptomycin, and para-amino-salicylic acid showed no such change, nor did one case treated with Chloromycetin. Despite the severe debilitating febrile courses associated with anorexia and marked weight loss in the patients with tuberculosis, no fatty metamorphosis of the liver similar to that following aureomycin therapy was seen.
4. The findings suggest that aureomycin may induce a reversible fatty metamorphosis of the liver.
